
In 2006 Novartis won a 220-million-dollar contract from the US health authorities concerning the development of a new type of flu, and in 2009 the same authorities invested 487 million dollars in the company’s US production facilities.
And now the FDA has approved Novartis’ flu-vaccine, Flucelvax, the first of its kind, produced with a completely new technology. It happens after an FDA advisory panel did not recommend the vaccine for approval in November 2009, saying more safety data was needed.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app